Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Drug Metabolism and Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2133/DMPK.24.3PMID 19252332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

  2009cited by this paper
• Impact of plasma-protein binding on receptor occupancy: an analytical description.

  2009cited by this paper
• Pharmacokinetic–Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

  2009cited by this paper
• Pharmacokinetic–pharmacodynamic modelling of fluvoxamine 5‐HT transporter occupancy in rat frontal cortex

  2008cited by this paper
• Development of Translational Pharmacokinetic–Pharmacodynamic Models

  2008cited by this paper
• Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and Morphine

  2008cited by this paper
• PK/PD: new insights for antibacterial and antiviral applications.

  2008cited by this paper
• Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006

  2008cited by this paper
• Residence time of receptor-ligand complexes and its effect on biological function.

  2008cited by this paper
• Microdialysis sampling method for evaluation of binding kinetics of small molecules to macromolecules.

  2008cited by this paper
• Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics

  2008cited by this paper
• Agonist binding, agonist affinity and agonist efficacy at G protein‐coupled receptors

  2008cited by this paper
• A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.

  2008cited by this paper
• PK/PD modelling and simulations: utility in drug development.

  2008cited by this paper
• Mechanism-Based Pharmacodynamic Modeling of S(–)-Atenolol: Estimation of in Vivo Affinity for the β1-Adrenoceptor with an Agonist-Antagonist Interaction Model

  2008cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

  2008cited by this paper
• Mechanism‐based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers

  2007cited by this paper
• Integrated Pharmacokinetics and Pharmacodynamics in Drug Development

  2007cited by this paper
• Drug–target residence time and its implications for lead optimization

  2007cited by this paper
• Effective Integration of Systems Biology, Biomarkers, Biosimulation, and Modeling in Streamlining Drug Development

  2007cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

  2007cited by this paper
• Tissue concentrations: do we ever learn?

  2007cited by this paper
• Translational research in the pharmaceutical industry: from theory to reality.

  2007cited by this paper
• Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat

  2007cited by this paper
• Model‐based Drug Development

  2007cited by this paper
• Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

  2007cited by this paper
• Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)

  2007cited by this paper
• The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

  2007cited by this paper
• AAPS‐FDA Workshop White Paper: Microdialysis Principles, Application, and Regulatory Perspectives

  2007cited by this paper
• Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine

  2007cited by this paper
• Population pharmacokinetic modelling of non‐linear brain distribution of morphine: influence of active saturable influx and P‐glycoprotein mediated efflux

  2007cited by this paper
• Influence of biophase distribution and P‐glycoprotein interaction on pharmacokinetic‐pharmacodynamic modelling of the effects of morphine on the EEG

  2007cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

  2007cited by this paper
• Allometric Scaling of Pharmacodynamic Responses: Application to 5-Ht1A Receptor Mediated Responses from Rat to Man

  2007cited by this paper
• Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

  2006cited by this paper
• Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers

  2006cited by this paper
• Target-mediated drug disposition and dynamics.

  2006cited by this paper
• Drug–target residence time and its implications for lead optimization

  2006cited by this paper
• Estimating the parameters of the operational model of pharmacological agonism

  2006cited by this paper
• Model-Based Drug Development: The Road to Quantitative Pharmacology

  2006cited by this paper
• Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats

  2006cited by this paper
• AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives

  2006cited by this paper
• The receptor concept: pharmacology's big idea

  2006cited by this paper
• Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.

  2006cited by this paper
• Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling

  2005cited by this paper
• Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.

  2005cited by this paper
• Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation

  2005cited by this paper
• Disease System Analysis: Basic Disease Progression Models in Degenerative Disease

  2005cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics

  2005cited by this paper
• Population Pharmacokinetic Analysis for Simultaneous Determination of Bmax and KDIn Vivo by Positron Emission Tomography

  2005cited by this paper
• A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data

  2005cited by this paper
• Systems biology in drug discovery

  2004cited by this paper
• Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

  2004cited by this paper
• The role of drug transporters at the blood-brain barrier.

  2003cited by this paper
• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations

  2003cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats.

  2002cited by this paper
• Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.

  2001cited by this paper
• Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool.

  2001cited by this paper
• Utilisation of Pharmacokinetic-Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making

  2001cited by this paper
• Drug treatment effects on disease progression.

  2001cited by this paper
• Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.

  2000cited by this paper
• Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon.

  2000cited by this paper
• Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo

  2000cited by this paper
• In vivo estimates of efficacy at 5-HT1A receptors: effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats

  2000cited by this paper
• Analysis of receptor inactivation experiments with the operational model of agonism yields correlated estimates of agonist affinity and efficacy.

  1999cited by this paper
• Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.

  1999cited by this paper
• Mechanism-Based Modeling of Adaptive Changes in the Pharmacodynamics of Midazolam in the Kindling Model of Epilepsy

  1999cited by this paper
• Characterization of the Pharmacodynamic Interaction between Parent Drug and Active Metabolite In Vivo: Midazolam and α-OH-Midazolam

  1999cited by this paper
• The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model.

  1999cited by this paper
• Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.

  1998cited by this paper
• Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development

  1997cited by this paper
• On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation.

  1997cited by this paper
• Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.

  1997cited by this paper
• The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.

  1996cited by this paper
• The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description

  1996cited by this paper
• Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for α1-adrenoceptor-mediated pressor activity

  1996cited by this paper
• Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients.

  1996cited by this paper
• Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle

  1995cited by this paper
• Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding.

  1995cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model‐fitting approach

  1993cited by this paper
• Estimation of agonist affinity and efficacy by direct, operational model-fitting.

  1990cited by this paper
• Estimation of ligand binding parameters by simultaneous fitting of association and dissociation data: a Monte Carlo simulation study.

  1989cited by this paper
• The kinetics of competitive radioligand binding predicted by the law of mass action.

  1984cited by this paper
• Operational models of pharmacological agonism

  1983cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

  1980cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine

  1979cited by this paper
• Mechanism-based pharmacokinetic–pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104:1232–1242 (2006). and Safety of Buprenorphine and Fentanyl

  year unknowncited by this paper

• Cumulative effect of stress on decisional exploration-to-exploitation switch assessed through a gambling task in female mice.

  2025cites this paper
• Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index.

  2024cites this paper
• A Quantitative Approach for Assessing Multidrug Resistance in Cancer

  2024cites this paper
• LC-MS/MS quantification of ropivacaine and local analgesic and adverse effects of Long-acting Ropivacaine Injection based on pharmacokinetic-pharmacodynamic modelling in Bama minipigs.

  2023cites this paper
• New Methodology for Determining Plasma Protein Binding Kinetics Using an Enzyme Reporter Assay Coupling with High-Resolution Mass Spectrometry.

  2023cites this paper
• Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood – Brain Barrier of Mice S

  2022cites this paper
• Mechanism-based pharmacodynamic model for propofol haemodynamic effects in healthy volunteers☆.

  2022cites this paper
• Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial

  2022cites this paper
• Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood–Brain Barrier of Mice

  2022cites this paper
• “Less is more”: A dose-response account of intranasal oxytocin pharmacodynamics in the human brain

  2021cites this paper
• Development of an intracellular quantitative assay to measure compound binding kinetics.

  2021cites this paper
• Dose Predictions for Drug Design.

  2020cites this paper
• Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease

  2020cites this paper
• Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs.

  2020cites this paper
• Neuromodulation of Mu-opioid Receptor (MOR-1) Gene(OPRM1) Alternatively-Spliced Variants Following Exposure toMorphine with Alma Fig (Ficus carica) Leaf Extract in HumanNeuroblastoma (SH-SY5Y) Cells: Review & Pilot Study

  2020cites this paper
• Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).

  2019cites this paper
• Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA

  2019cites this paper
• Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC

  2018cites this paper
• Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

  2018cites this paper
• Analysis of Biased Agonism.

  2018cites this paper
• Increased Cerebral Blood Flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles

  2018cites this paper
• Modelling the delay between PK and EEG effects of morphine in rats ; binding kinetic versus effect compartment models

  2018cites this paper
• Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

  2018cites this paper
• An Introduction to Systems Biology and Quantitative Systems Pharmacology

  2017cites this paper
• Data Sharing in the Pharmaceutical Enterprise: The Genie's Out of the Bottle.

  2017cites this paper
• Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics

  2017cites this paper
• Pharmacokinetic–Pharmacodynamic Modelling of Anesthetic Drugs

  2017cites this paper
• Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.

  2017cites this paper
• Biomarkers in epilepsy–A modelling perspective

  2017cites this paper
• Approaching Pharmacometrics as a Paleontologist Would: Recovering the Links Between Drugs and the Body Through Reconstruction

  2016cites this paper
• Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go

  2016cites this paper
• Development of hysteresis analysis as a model-independent approach to assess temporal dissociation in pharmacokinetics and pharmacodynamics

  2016cites this paper
• Intracellular Delivery III

  2016cites this paper
• PBPK Modelling of Intracellular Drug Delivery Through Active and Passive Transport Processes

  2016cites this paper
• Elvitegravir/Cobicistat-Associated Toxic Optical Neuropathy in an HIV-Infected Patient: A Call for Caution?

  2016cites this paper
• Systems pharmacology - Towards the modeling of network interactions.

  2016cites this paper
• Parameter Identifiability of Fundamental Pharmacodynamic Models

  2016cites this paper
• Model of the Interaction between Ligand and Receptor in the Brain

  2016cites this paper
• Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models

  2015cites this paper
• The drug–target residence time model: a 10-year retrospective

  2015cites this paper
• OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

  2015cites this paper
• Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery.

  2015cites this paper
• Quantitative Approaches in Translational Research: An Overview

  2015cites this paper
• Molecular mechanism matters: Benefits of mechanistic computational models for drug development.

  2015cites this paper
• Determination of in Vivo Enzyme Occupancy Utilizing Inhibitor Dissociation Kinetics.

  2015cites this paper
• Pharmacokinetics of CNS Penetration

  2015cites this paper
• Drug Discoveries and Molecular Mechanism of Action

  2015cites this paper
• Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development—Opportunities and challenges

  2015cites this paper
• Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned

  2014cites this paper
• Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice

  2014cites this paper
• Towards predictive cardiovascular safety : a systems pharmacology approach

  2014cites this paper
• A systems pharmacology approach for predicting drug-induced changes in hemodynamic variables

  2014cites this paper
• PKPD Aspects of Brain Drug Delivery in a Translational Perspective

  2014cites this paper
• Effect of disease states on α1‐adrenoceptor binding and signal transduction parameters in isolated perfused heart: quantification by pharmacokinetic‐pharmacodynamic modelling

  2014cites this paper
• Pharmacometrics in Psychiatric Diseases

  2014cites this paper
• Pharmacometrics in Cardiovascular Safety

  2014cites this paper
• Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

  2014cites this paper
• Towards predictive cardiovascular safety : a systems pharmacology approach

  2014cites this paper
• Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradigm and Assessment of Drug–Transporter Interactions

  2014cites this paper
• Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

  2014cites this paper
• PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

  2013cites this paper
• Overview of Experimental Models of the Blood‐Brain Barrier in CNS Drug Discovery

  2013cites this paper
• Pharmacokinetics and the drug-target residence time concept.

  2013cites this paper
• A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation

  2013cites this paper
• Translational Approaches for Predicting CNS Drug Effects Using Microdialysis

  2013cites this paper
• Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth

  2013cites this paper
• The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects

  2013cites this paper
• Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

  2012cites this paper
• Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

  2012cites this paper
• High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway.

  2012cites this paper
• Pharmacokinetics/pharmacodynamics model-supported early drug development.

  2012cites this paper
• Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations

  2012cites this paper
• Translational pharmacology of intranasal administration of dopamine receptor agonists and antagonists

  2011cites this paper
• Inhibition of Snowshoe Hare Succinate Dehydrogenase Activity as a Mechanism of Deterrence for Papyriferic Acid in Birch

  2011cites this paper
• Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

  2011cites this paper
• Disease Progression Analysis: Towards Mechanism-Based Models

  2011cites this paper
• lililllffinlbition of §now§lffioe JHfaure §lUiccilillate Delffiydllrogelilla§e Activity a§ a Meclffialilln§m of Deterrelillce for JP>apyrftferic Acid

  2011cites this paper
• Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.

  2011cites this paper
• Translational research in drug discovery, research and development

  2010cites this paper
• Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time

  2010cites this paper
• Assessment of the blood-brain barrier in CNS drug discovery.

  2010cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice (cid:1)

  2010cites this paper
• Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action

  2010cites this paper
• In vivo rat PK profiling in drug discovery: new challenges

  2010cites this paper
• Integrating cell-level kinetic modeling into the optimization of cancer therapeutics

  2010cites this paper
• Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine

  2010cites this paper
• The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety

  2010cites this paper
• The role of the blood-CNS barrier in CNS disorders and their treatment.

  2010cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice

  2009cites this paper
• Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development.

  2009cites this paper
• Recommendations : Soluble biomarker assessments in clinical trials in osteoarthritis

  year unknowncites this paper